hrcak mascot   Srce   HID

Pregledni rad

HISTRELIN ACETATE – THE FIRST ONCE YEARLY LHRH AGONIST

Silvio Altarac

Puni tekst: hrvatski, pdf (117 KB) str. 0-0 preuzimanja: 100* citiraj
APA 6th Edition
Altarac, S. (2011). HISTRELIN ACETAT – PRVI LHRH-AGONIST S PRIMJENOM JEDNOM NA GODINU. Liječnički vjesnik, 133 (9-10), 0-0. Preuzeto s https://hrcak.srce.hr/171849
MLA 8th Edition
Altarac, Silvio. "HISTRELIN ACETAT – PRVI LHRH-AGONIST S PRIMJENOM JEDNOM NA GODINU." Liječnički vjesnik, vol. 133, br. 9-10, 2011, str. 0-0. https://hrcak.srce.hr/171849. Citirano 16.10.2019.
Chicago 17th Edition
Altarac, Silvio. "HISTRELIN ACETAT – PRVI LHRH-AGONIST S PRIMJENOM JEDNOM NA GODINU." Liječnički vjesnik 133, br. 9-10 (2011): 0-0. https://hrcak.srce.hr/171849
Harvard
Altarac, S. (2011). 'HISTRELIN ACETAT – PRVI LHRH-AGONIST S PRIMJENOM JEDNOM NA GODINU', Liječnički vjesnik, 133(9-10), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171849 (Datum pristupa: 16.10.2019.)
Vancouver
Altarac S. HISTRELIN ACETAT – PRVI LHRH-AGONIST S PRIMJENOM JEDNOM NA GODINU. Liječnički vjesnik [Internet]. 2011 [pristupljeno 16.10.2019.];133(9-10):0-0. Dostupno na: https://hrcak.srce.hr/171849
IEEE
S. Altarac, "HISTRELIN ACETAT – PRVI LHRH-AGONIST S PRIMJENOM JEDNOM NA GODINU", Liječnički vjesnik, vol.133, br. 9-10, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171849. [Citirano: 16.10.2019.]

Sažetak
Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leuprolide, goserelin, triptorelin, degarelix and buserelin were administered as either intramuscular or subcutaneous depot injections on a 1, 2, 3 or 6 months basis. Histrelin acetate is the first long-acting luteinising hormone-releasing hormone agonist available as a once-yearly subcutaneous implant.

Ključne riječi
Gonadotropin-releasing hormone – analogs and dirivatives, therapeutic use, administration and dosage; Antineoplastic agents, hormonal – therapeutic use, administration and dosage; Prostatic neoplasms – therapeutic use, pathology; Androgen antagonists – therapeutic use; Testosterone – blood, antagonists and inhibitors; Drug implants

Hrčak ID: 171849

URI
https://hrcak.srce.hr/171849

[hrvatski]

Posjeta: 152 *